PCSK9抑制剂:一个专利审查 2018-2023
Enrico Mario Alessandro Fassi1, Andrea Citarella2, Marco Albani1
1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milano, Italy.
Expert opinion on therapeutic patents
|April 8, 2024
概括
抑制蛋白转化酶亚素/素9 (PCSK9) 的新型化合物已获得专利,用于治疗高胆固醇血症. 这些新的PCSK9抑制剂在心血管疾病市场上面临着先进生物制剂的竞争.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 蛋白转化酶亚素/素9 (PCSK9) 调节肝脏低密度脂蛋白受体 (LDLR) 的水平.
- 抑制PCSK9是管理高胆固醇和心血管疾病的有效策略.
- 许多机构正在开发新的PCSK9抑制剂.
研究的目的:
- 审查2018年至2023年6月期间披露的新型PCSK9抑制剂的专利文献.
- 分析新兴的PCSK9向化合物的风景.
主要方法:
- 在espacenet数据库中搜索与PCSK9抑制剂相关的专利文件.
- 包括2018年至2023年6月出版的专利,来自100多个专利权威机构.
主要成果:
- 识别了声称用于PCSK9抑制的新化学框架的专利文献.
- 观察到,虽然一些化合物正在临床试验中,但没有一个化合物完成了临床试验.
- 他注意到现有单克隆抗体和siRNA疗法的竞争性市场.
结论:
- 新型PCSK9抑制剂的开发正在进行中,具有显著的专利活动.
- 新的PCSK9抑制剂在一个由先进的生物制剂和既定疗法主导的市场上面临挑战.
- 这些专利化合物需要进一步的临床进展,以建立其治疗和市场地位.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K